• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

C-3 halo and 3-methyl substituted 5'-nor-3-deazaaristeromycins: Synthesis and antiviral properties

tetano

Editor, Senior Moderator
Bioorg Med Chem. 2012 Oct 22. pii: S0968-0896(12)00772-9. doi: 10.1016/j.bmc.2012.09.051. [Epub ahead of print]
C-3 halo and 3-methyl substituted 5'-nor-3-deazaaristeromycins: Synthesis and antiviral properties.
Liu C, Chen Q, Yang M, Schneller SW.
Source

Molette Laboratory for Drug Discovery, Department of Chemistry and Biochemistry, Auburn University, Auburn, AL 36849-5312, United States.
Abstract

To expand on the antiviral properties of 5'-noraristeromycin, synthetic entry into 3-substituted 3-deaza-5'-noraristeromyin derivatives (i.e., bromo, 4; iodo, 5; chloro, 6; and, methyl, 7) has been accomplished from a common intermediate. An extensive antiviral analysis showed 7 to be basically inactive (except for weak effects against VSV) and there were no general trends among the halo compounds (except versus reovirus-1 and influenza B). Individually, compound 4 was most favorable towards HCMV, VZV, HBV, and VV; product 5 against HBV, VSV, VV, influenza B, HCMV, and measles; and, target 6 towards Punta Toro, VSV, measles, parainflucenza-3, influenza A (H5N1), and influenza B. The methyl target 7 was inactive in all viral assays.

Copyright ? 2012 Elsevier Ltd. All rights reserved.

PMID:
23176752
[PubMed - as supplied by publisher]

http://www.ncbi.nlm.nih.gov/pubmed/23176752
 
Back
Top Bottom